Pressure Mounts to Lift Patent Protections on Coronavirus Vaccines
President Biden and drugmakers are facing demands from liberal activists and global leaders to suspend intellectual property rights on the vaccines as the pandemic surges.
The debate on waiving an international intellectual property agreement that protects pharmaceutical trade secrets is both a political and a practical problem for President Biden, who has vowed to restore the U.S. as a leader in global health.Credit.Saul Martinez for The New York Times
Published May 3, 2021Updated May 17, 2021
WASHINGTON President Biden, faced with surging Covid-19 crises in India and South America, is under intensifying pressure from the international community and his party’s left flank to commit to increasing the vaccine supply by loosening patent and intellectual property protections on coronavirus vaccines.
Biden Confronts Coronavirus Vaccine Patents
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
Amgen Inc (AMGN) Q1 2021 Earnings Call Transcript Motley Fool Transcribers © The Motley Fool Logo of jester cap with thought bubble.
Amgen Inc (NASDAQ: AMGN)
Operator
My name is Erica, and I will be your conference facilitator today for Amgen s First Quarter 2021 Financial Results Conference Call. [Operator Instructions]
I would now like to introduce Arvind Sood, Vice President of Investor Relations. Mr. Sood, you may now begin.SPONSORED:
10 stocks we like better than Amgen
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade,
GlaxoSmithKline plc (GSK) Q1 2021 Earnings Call Transcript Motley Fool Transcribers © The Motley Fool Logo of jester cap with thought bubble.
GlaxoSmithKline plc (NYSE: GSK)
Operator
Good afternoon, ladies and gentlemen. And welcome to the Analyst Call on the GSK First Quarter 2021 Results. I will now hand you over to Iain Mackay, our CFO, who will introduce today s session.SPONSORED:
10 stocks we like better than GlaxoSmithKline
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade,
Motley Fool Stock Advisor, has tripled the market.
Dive Brief:
Drug sales at Amgen were down 5% during the first quarter, results which the company pinned on several factors, including price cuts and the lingering effects of the coronavirus pandemic.
In an earnings presentation Tuesday, Amgen reported $5.6 billion in sales, down from the $5.9 billion reported over the same three-month period last year. Though a handful of Amgen s drugs achieved double-digit growth, including the bone loss therapy Prolia and the cholesterol medicine Repatha, overall, more than half of its top-selling products posted year-over-year sales declines.
Total revenue of $5.9 billion was also below what Wall Street had expected for the quarter. Looking ahead, analysts fear the headwinds facing Amgen won t let up anytime soon. Geoffrey Porges, an analyst at SVB Leerink, wrote to clients that there are multiple negative trends in their core business that could persist through most of the year.
vimarsana © 2020. All Rights Reserved.